Prognosis of radiation-induced bone sarcoma is similar to primary osteosarcoma.
Radiation-induced sarcoma of bone (RISB) is thought to be associated with a poor prognosis. The purpose of this study was to determine disease-free and overall survival of patients treated for RISB, and whether there is a role for limb sparing surgery. Twenty-four patients had a mean latency of 16 years between radiation for their index cancer and RISB diagnosis. The most common tumor was osteosarcoma (n = 17). Ten patients with localized disease treated aggressively with chemotherapy and surgical resection had estimated 5-year disease-free and overall survival rates of 58% and 69% respectively. Patients treated by surgery alone or those with metastases at diagnosis had inferior outcomes. Patients who received a complete course of chemotherapy demonstrated better histologic tumor response and improved survival. There was no difference in survival between the limb sparing surgery (n = 12) or amputation (n = 8) groups. However, limb salvage patients had slightly higher rates of local tumor relapse and post-operative complications. Functional outcome following limb sparing surgery for 10 patients with RISB was similar to a matched cohort treated for primary osteosarcoma. An aggressive treatment approach for patients with RISB may provide similar rates of local recurrence and metastasis and functional outcomes compared to patients with primary osteosarcoma.


METHODS
Therapeutic study, level IV-1.
Shaheen
Mahmood
M
University Musculoskeletal Oncology Unit, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, Canada.
Deheshi
Benjamin M
BM
Riad
Soha
S
Werier
Joel
J
Holt
Ginger E
GE
Ferguson
Peter C
PC
Wunder
Jay S
JS
D000293:Adolescent; D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000401:mortality*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D009381:Neoplasms, Radiation-Induced / Q000401:mortality*; D012516:Osteosarcoma / Q000401:mortality*; D011379:Prognosis; D012509:Sarcoma / Q000401:mortality*; D016896:Treatment Outcome